RAPT Therapeutics Reports Third Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St set for higher open but weekly losses loom
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Leerink Partners Reiterates Market Perform Rating on Rapt Therapeutics (RAPT)
November 12, 2024 4:08 PM ESTLeerink Partners analyst Thomas Smith reiterated a Market Perform rating and $2.00 price target on Rapt Therapeutics (NASDAQ: RAPT).
The analyst comments "Bottom Line: RAPT reported 3Q24 financial results following the company's decision to terminate development of zelnecirnon (RPT193, oral CCR4 antagonist) based on recent FDA feedback suggesting there was no viable path forward for this program (see our note HERE).... More
Stifel Downgrades Rapt Therapeutics (RAPT) to Hold
November 12, 2024 4:04 PM ESTStifel analyst Alex Thompson downgraded Rapt Therapeutics (NASDAQ: RAPT) from Buy to Hold with a price target of $2.00 (from $7.00).
The analyst comments "We are downgrading RAPT to Hold following the recent Zelnecirnon program termination (LINK). RAPT discontinued the program following FDA feedback suggesting... More
